SCHEMBL8745007

SCHEMBL8745007

N#COC(=O)C=Cc1ccc(O)c(O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 8/20 0.64
▸ TTR P02766 5/20 0.64
▸ PTPN1 P18031 2/20 0.60
▸ DPP4 P27487 2/20 0.59
▸ HSD17B10 Q99714 3/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ TP53 P04637 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ AKR1B10 O60218 2/20 0.57
▸ AKR1B1 P15121 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ HDAC3 O15379 1/20 0.57
▸ CA12 O43570 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ MMP1 P03956 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5054536 0.84 EPHX2 (0.72) APPHSD17B10TDP1TP53ALOX15
SCHEMBL1299521 0.81 CA12 (0.61) DPP4AKR1B10AKR1B1HDAC3CA12
SCHEMBL2547176 0.81 CA12 (0.61) DPP4AKR1B10AKR1B1HDAC3CA12
Methylcaffeate SCHEMBL28177340 0.81 APP (0.85) APPTTRPTPN1DPP4HSD17B10
SCHEMBL17372826 0.81 APP (0.74) APPTTRPTPN1DPP4HSD17B10
SCHEMBL28541801 0.81 APP (0.74) APPTTRPTPN1DPP4HSD17B10
SCHEMBL27779815 0.81 APP (0.74) APPTTRPTPN1DPP4HSD17B10
SCHEMBL30665840 0.81 AKR1B10 (0.52) KDM4EAKR1B10AKR1B1MMP1MMP2
SCHEMBL23681099 0.80 TTR (0.67) APPTTRPTPN1DPP4HSD17B10
SCHEMBL30628154 0.80 TTR (0.67) APPTTRPTPN1DPP4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0754038-A1 USE OF BENZYLIDENE-MALONONITRILE DERIVATES FOR THE TREATMENT OF LEUKEMIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1997-01-22 — — EP disclosed
WO-1995028922-A1 USE OF BENZYLIDENE-MALONONITRILE DERIVATES FOR THE TREATMENT OF LEUKEMIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-11-02 — — WO disclosed
Send feedback